Hepatitis B surface antigen (HBsAg) is a protein found on the surface of the hepatitis B virus. It can be detected in high levels in the blood during both acute and chronic hepatitis B virus infections. The presence of HBsAg indicates that the person is capable of spreading the infection to others. Normally, the body produces antibodies to HBsAg as part of the immune response to the infection. HBsAg is also used to create the hepatitis B vaccine.

Hepatitis B surface antibody (anti-HBs) indicates that a person has recovered from the hepatitis B virus infection and is now immune to it. This antibody can also develop in individuals who have been successfully vaccinated against hepatitis B.

Total hepatitis B core antibody (anti-HBc) appears when symptoms of acute hepatitis B begin and remains present for life. The presence of anti-HBc indicates that a person has either had a previous or ongoing infection with the hepatitis B virus, although the exact time frame cannot be determined. This antibody is not present in individuals who have received the hepatitis B vaccine.

IgM antibody to hepatitis B core antigen (IgM anti-HBc) indicates a recent infection or acute hepatitis B. If this antibody is present, it suggests that the infection occurred within the past six months.

Hepatitis B surface antigen (HBsAg) is a protein found on the surface of the hepatitis B virus. It can be detected in high levels in the blood during both acute and chronic hepatitis B virus infections. The presence of HBsAg indicates that the person is capable of spreading the infection to others. Normally, the body produces antibodies to HBsAg as part of the immune response to the infection. HBsAg is also used to create the hepatitis B vaccine.

Hepatitis B surface antibody (anti-HBs) indicates that a person has recovered from the hepatitis B virus infection and is now immune to it. This antibody can also develop in individuals who have been successfully vaccinated against hepatitis B.

Total hepatitis B core antibody (anti-HBc) appears when symptoms of acute hepatitis B begin and remains present for life. The presence of anti-HBc indicates that a person has either had a previous or ongoing infection with the hepatitis B virus, although the exact time frame cannot be determined. This antibody is not present in individuals who have received the hepatitis B vaccine.

IgM antibody to hepatitis B core antigen (IgM anti-HBc) indicates a recent infection or acute hepatitis B. If this antibody is present, it suggests that the infection occurred within the past six months.

Functional abdominal pain is a common issue among children in this age group. The pain can occur in episodes or be continuous. In order to diagnose functional abdominal pain, it is important to rule out any inflammatory, anatomical, metabolic, or neoplastic causes that could explain the symptoms. The criteria for diagnosis must be met at least once a week for a minimum of two months.

If the pain is present for at least 25% of the time and there is a loss of daily functioning, it is referred to as functional abdominal pain syndrome. In this syndrome, additional somatic symptoms such as headache, limb pain, or sleep disturbance are often present.

For a diagnosis of irritable bowel syndrome, the pain must also improve with defecation or be associated with changes in the frequency and form of stools.

School refusal is typically not associated with pain outside of school time. Since this child is experiencing pain on weekends, it makes the diagnosis of school refusal less likely.

Abdominal migraine is characterized by intense, acute periumbilical pain that occurs in paroxysmal episodes lasting over an hour. Patients generally have periods of wellness lasting weeks to months between attacks. The pain is often accompanied by anorexia, nausea, vomiting, headache, photophobia, and pallor.

Based on the child’s well-being, normal examination, and blood tests, a diagnosis of coeliac disease seems unlikely in this case.

Clostridium difficile is a type of bacteria that is Gram-positive, anaerobic, and capable of forming spores. It is commonly associated with diarrhoea, which occurs after the use of broad-spectrum antibiotics. These antibiotics disrupt the normal bacteria flora in the bowel, allowing Clostridium difficile to multiply. As a result, the mucosa of the large intestine becomes inflamed and bleeds, leading to a distinct ‘pseudomembranous appearance’. The main symptoms of Clostridium difficile infection include abdominal cramps, bloody and/or watery diarrhoea, and fever. It is worth noting that over 80% of Clostridium difficile infections are reported in individuals aged 65 and above.

The cytotoxin assay is currently considered the gold standard for diagnosing Clostridium difficile colitis. However, this test has its drawbacks, as it can be challenging to perform and the results may take up to 48 hours to be available. An alternative laboratory test commonly used for diagnosis is an enzyme-mediated immunoassay that detects toxins A and B. This test has a specificity ranging from 93% to 100% and a sensitivity ranging from 63% to 99%.

It is important to note that alcohol hand gel is ineffective against Clostridium difficile spores. Therefore, healthcare providers who come into contact with this bacteria must wash their hands with soap and water to ensure proper hygiene.

Hepatic encephalopathy is a condition caused by the accumulation of nitrogenous waste products in the body due to impaired liver function. These waste products cross the blood brain barrier and contribute to the production of glutamine, leading to changes in astrocyte osmotic pressure, brain edema, and neurotransmitter dysfunction.

To address hepatic encephalopathy, the first-line drugs used are Rifaximin and lactulose. Rifaximin is an oral antibiotic that helps reduce the presence of ammonia-producing bacteria in the intestines. Lactulose, on the other hand, converts soluble ammonia into insoluble ammonium and aids in relieving constipation.

It is important to note that Chlordiazepoxide, a benzodiazepine, may be used to treat alcohol withdrawal but should be avoided in cases of hepatic encephalopathy as it can worsen the condition.

Further Reading:

Cirrhosis is a condition where the liver undergoes structural changes, resulting in dysfunction of its normal functions. It can be classified as either compensated or decompensated. Compensated cirrhosis refers to a stage where the liver can still function effectively with minimal symptoms, while decompensated cirrhosis is when the liver damage is severe and clinical complications are present.

Cirrhosis develops over a period of several years due to repeated insults to the liver. Risk factors for cirrhosis include alcohol misuse, hepatitis B and C infection, obesity, type 2 diabetes, autoimmune liver disease, genetic conditions, certain medications, and other rare conditions.

The prognosis of cirrhosis can be assessed using the Child-Pugh score, which predicts mortality based on parameters such as bilirubin levels, albumin levels, INR, ascites, and encephalopathy. The score ranges from A to C, with higher scores indicating a poorer prognosis.

Complications of cirrhosis include portal hypertension, ascites, hepatic encephalopathy, variceal hemorrhage, increased infection risk, hepatocellular carcinoma, and cardiovascular complications.

Diagnosis of cirrhosis is typically done through liver function tests, blood tests, viral hepatitis screening, and imaging techniques such as transient elastography or acoustic radiation force impulse imaging. Liver biopsy may also be performed in some cases.

Management of cirrhosis involves treating the underlying cause, controlling risk factors, and monitoring for complications. Complications such as ascites, spontaneous bacterial peritonitis, oesophageal varices, and hepatic encephalopathy require specific management strategies.

Overall, cirrhosis is a progressive condition that requires ongoing monitoring and management to prevent further complications and improve outcomes for patients.

According to the latest guidelines from NICE and the BNF, the recommended initial treatment for typhoid fever is cefotaxime. It is important to note that infections originating from the Middle-East, South Asia, and South-East Asia may have multiple antibiotic resistance, so it is advisable to test for sensitivity. In cases where the microorganism is found to be sensitive, ciprofloxacin can be considered as a suitable alternative.

Clostridium difficile is a type of bacteria that is Gram-positive, anaerobic, and capable of forming spores. C. difficile bacteria are found in the digestive system of about 1 in every 30 healthy adults.

Clostridium difficile associated diarrhea (CDAD) often occurs after the use of broad-spectrum antibiotics, which disrupt the normal balance of bacteria in the gut and allow Clostridium difficile to multiply. This leads to inflammation and bleeding of the large intestine, resulting in a distinct pseudomembranous appearance. The majority of Clostridium difficile infections, over 80%, are reported in individuals aged 65 and older.

The main symptoms of CDAD include abdominal cramps, severe bloody and/or watery diarrhea, offensive-smelling diarrhea, and fever. To diagnose Clostridium difficile colitis, the current gold standard is the cytotoxin assay. However, this test can be challenging to perform and results may take up to 48 hours to obtain. An alternative laboratory test is an enzyme-mediated immunoassay that detects toxins A and B, which has a specificity of 93-100% and a sensitivity of 63-99%.

If left untreated, CDAD can progress to toxic megacolon, a condition that can be fatal, particularly in frail or elderly patients.

For more information, you can refer to the guidance provided by the National Institute for Health and Care Excellence (NICE) regarding the risk of Clostridium difficile infection associated with the use of broad-spectrum antibiotics.

If someone with IBS experiences unintentional weight loss or rectal bleeding, it is important to investigate further as these symptoms are not typical of IBS and may indicate a more serious underlying condition. Other alarm symptoms to watch out for include positive faecal immunochemical test (FIT), change in bowel habit after the age of 60, elevated faecal calprotectin levels, iron deficiency anaemia, persistent or frequent bloating in females (especially if over 50), the presence of an abdominal or rectal mass, or a family history of bowel cancer, ovarian cancer, coeliac disease, or inflammatory bowel disease.

Further Reading:

Irritable bowel syndrome (IBS) is a chronic disorder that affects the interaction between the gut and the brain. The exact cause of IBS is not fully understood, but factors such as genetics, drug use, enteric infections, diet, and psychosocial factors are believed to play a role. The main symptoms of IBS include abdominal pain, changes in stool form and/or frequency, and bloating. IBS can be classified into subtypes based on the predominant stool type, including diarrhea-predominant, constipation-predominant, mixed, and unclassified.

Diagnosing IBS involves using the Rome IV criteria, which includes recurrent abdominal pain associated with changes in stool frequency and form. It is important to rule out other more serious conditions that may mimic IBS through a thorough history, physical examination, and appropriate investigations. Treatment for IBS primarily involves diet and lifestyle modifications. Patients are advised to eat regular meals with a healthy, balanced diet and adjust their fiber intake based on symptoms. A low FODMAP diet may be trialed, and a dietician may be consulted for guidance. Regular physical activity and weight management are also recommended.

Psychosocial factors, such as stress, anxiety, and depression, should be addressed and managed appropriately. If constipation is a predominant symptom, soluble fiber supplements or foods high in soluble fiber may be recommended. Laxatives can be considered if constipation persists, and linaclotide may be tried if optimal doses of previous laxatives have not been effective. Antimotility drugs like loperamide can be used for diarrhea, and antispasmodic drugs or low-dose tricyclic antidepressants may be prescribed for abdominal pain. If symptoms persist or are refractory to treatment, alternative diagnoses should be considered, and referral to a specialist may be necessary.

Overall, the management of IBS should be individualized based on the patient’s symptoms and psychosocial situation. Clear explanation of the condition and providing resources for patient education, such as the NHS patient information leaflet and support from organizations like The IBS Network, can also be beneficial.

Ulcerative colitis is a condition that is less common among smokers, as around 70-80% of individuals affected by this disease are non-smokers. There are several recognized associations of ulcerative colitis, including aphthous ulcers, uveitis and episcleritis, seronegative spondyloarthropathies, sacroiliitis, erythema nodosum, pyoderma gangrenosum, finger clubbing, autoimmune hemolytic anemia, primary biliary cirrhosis, primary sclerosing cholangitis, and chronic active hepatitis. These conditions often coexist with ulcerative colitis and can provide additional insight into the disease.

Spontaneous bacterial peritonitis (SBP) is a condition that occurs as a complication of ascites, which is the accumulation of fluid in the abdomen. SBP typically presents with various symptoms such as fevers, chills, nausea, vomiting, abdominal pain, general malaise, altered mental status, and worsening ascites. This patient is at risk of developing alcoholic liver disease and cirrhosis due to their harmful levels of alcohol consumption. Harmful drinking is defined as drinking ≥ 35 units a week for women or drinking ≥ 50 units a week for men. The presence of shifting dullness and a distended abdomen are consistent with the presence of ascites. SBP is an acute bacterial infection of the ascitic fluid that occurs without an obvious identifiable cause. It is one of the most commonly encountered bacterial infections in patients with cirrhosis. Signs and symptoms of SBP include fevers, chills, nausea, vomiting, abdominal pain and tenderness, general malaise, altered mental status, and worsening ascites.

Further Reading:

Cirrhosis is a condition where the liver undergoes structural changes, resulting in dysfunction of its normal functions. It can be classified as either compensated or decompensated. Compensated cirrhosis refers to a stage where the liver can still function effectively with minimal symptoms, while decompensated cirrhosis is when the liver damage is severe and clinical complications are present.

Cirrhosis develops over a period of several years due to repeated insults to the liver. Risk factors for cirrhosis include alcohol misuse, hepatitis B and C infection, obesity, type 2 diabetes, autoimmune liver disease, genetic conditions, certain medications, and other rare conditions.

The prognosis of cirrhosis can be assessed using the Child-Pugh score, which predicts mortality based on parameters such as bilirubin levels, albumin levels, INR, ascites, and encephalopathy. The score ranges from A to C, with higher scores indicating a poorer prognosis.

Complications of cirrhosis include portal hypertension, ascites, hepatic encephalopathy, variceal hemorrhage, increased infection risk, hepatocellular carcinoma, and cardiovascular complications.

Diagnosis of cirrhosis is typically done through liver function tests, blood tests, viral hepatitis screening, and imaging techniques such as transient elastography or acoustic radiation force impulse imaging. Liver biopsy may also be performed in some cases.

Management of cirrhosis involves treating the underlying cause, controlling risk factors, and monitoring for complications. Complications such as ascites, spontaneous bacterial peritonitis, oesophageal varices, and hepatic encephalopathy require specific management strategies.

Overall, cirrhosis is a progressive condition that requires ongoing monitoring and management to prevent further complications and improve outcomes for patients.